# Behavioral benefits of GSK-3β inhibition and state-dependent microtubule signatures in the Fmr1-KO mouse

**Authors:** John Kealy, Charlotte Callaghan, Aimée Freeburn, Aoife Thornton, Chris Greene, Beatrice Garrone, Claudio Milanese, Massimiliano Bianchi

PMC · DOI: 10.3389/fnins.2025.1643439 · Frontiers in Neuroscience · 2025-10-02

## TL;DR

Inhibiting GSK-3β improves certain behaviors in mice lacking the Fmr1 gene, which is linked to Fragile X syndrome.

## Contribution

This study demonstrates that GSK-3β inhibition can reduce perseverative behaviors and improve social interaction in Fmr1-KO mice.

## Key findings

- GSK-3β inhibitors reduced marble burying and improved social discrimination in Fmr1-KO male mice.
- Microtubule dynamics, as indicated by α-tubulin PTMs, were altered in Fmr1-KO mice and influenced by sex.
- Vehicle injections altered baseline behaviors and α-tubulin PTMs in Fmr1-KO mice.

## Abstract

Glycogen-synthase-kinase-3β (GSK-3β) and microtubule dynamics are implicated in Fragile X syndrome (FXS). We examined behaviors and hippocampal α-tubulin post-translational modifications (PTMs) in Fmr1-KO male mice without and with chronic administration of the GSK-3β inhibitors SB216763 (30 mg/kg, i.p.) and AF3581 (10 mg/kg, i.p.). Fmr1-KO male mice and wild-type (WT) were evaluated in the open field, marble-burying, elevated-plus-maze (EPM), novel-object-recognition (NOR) and three-chamber sociability test (3-CST); acetylated α-tubulin (Acet/Total-Tub) and tyrosinated/detyrosinated α-tubulin (Tyr/Glu-Tub) ratios were then analyzed. Fmr1-KO male showed hyperactivity, excessive marble burying and impaired NOR; Acet/Total-Tub was elevated and Tyr/Glu-Tub reduced vs. WT, indicating reduced microtubule dynamics. In a mixed-sex cohort bred female WT displayed lower Acet/Total-Tub and increased Tyr/Glu-Tub vs. male WT. The Fmr1-KO-associated decrease in Tyr/Glu-Tub was consistent across sexes. FMRP and synaptic markers were also analyzed in this cohort, spinophilin was found increased in both male and female Fmr1-KO. Fmr1-heterozygous females showed no molecular alterations, supporting the protective role of FMRP. Fmr1-KO male mice received vehicle or GSK-3β inhibitors and were tested in behavioral assays followed by α-tubulin PTMs analysis. Daily vehicle injections appeared to abolish baseline differences in hyperactivity, marble burying and α-tubulin PTMs. Under these conditions both inhibitors reduced marble burying. SB216763 normalized social discrimination in 3-CST, while AF3581 only produced a non-significant positive trend. Neither compound altered α-tubulin PTMs. These results show that GSK-3β inhibition has anti-perseverative and pro-social effects in Fmr1-KO male mice. However, behavioral and molecular endpoints, such as α-tubulin PTMs, appear to be sensitive to both genetic background and experimental procedures.

## Linked entities

- **Genes:** FMR1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 2332]
- **Proteins:** GSK3B (glycogen synthase kinase 3 beta), LOC126710533 (tubulin alpha chain-like), FMR1 (fragile X messenger ribonucleoprotein 1), ppp1r9b.L (protein phosphatase 1 regulatory subunit 9B L homeolog)
- **Chemicals:** SB216763 (PubChem CID 176158)
- **Diseases:** Fragile X syndrome (MONDO:0010383)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Fmr1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 14265] {aka FMRP, Fmr-1}, Tub (TUB bipartite transcription factor) [NCBI Gene 22141] {aka rd5}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 56637] {aka 7330414F15Rik, 8430431H08Rik, GSK-3, GSK-3beta, GSK3}, Ppp1r9b (protein phosphatase 1, regulatory subunit 9B) [NCBI Gene 217124] {aka SPL, Spn}
- **Diseases:** FXS (MESH:D005600), hyperactivity (MESH:D006948)
- **Chemicals:** Glu (MESH:D018698), SB216763 (MESH:C417521), Tyr (MESH:D014443), 3-CST (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12528152/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12528152/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12528152/full.md

---
Source: https://tomesphere.com/paper/PMC12528152